Replies to post #827666 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Excuses. Great biotech companies (even if they are pre revenue) raise money at increasing valuation. Particularly as they sit on the cusp of a major regulatory decision.

LP and her financiers love such bag holders though! ;)

[Steady_T]

It may or may not reduce shareholders ownership. That depends on what the shares buy in terms of assets for the company. A smaller slice of a larger pie if you will.

You seem to be allergic to anything that seems to be a positive outlook for anything.

If the company thinks that approval is indeed coming in the near future then spending money on the items that Skitaho listed would be a sound uses of funds. Preparing for product launch is called planning and executing.

And the idea that nobody could have anticipated a long MHRA review is too convenient.

A difficult review and a record setting review are very different things.

AFAIK NWBO has just set the record for the longest MAA process. Certainly if not THE longest then clearly in the running for the longest. That is inconvenient in the extreme.
Anyone can raise concerns. Obviously the MHRA has had questions about many things. The company has told us about the steady stream of questions. So far none of them have been fatal or the MAA would have been rejected by now.

[skitahoe]

I disagree with your statement that it needs the money to stay alive, it's true that it needs some money to do so, but it wasn't required to build a leukapheresis facility, nor is it required to tie up production facilities, or to initiate new trials. My point is that these things, and probably more that we don't yet know about, are needed to grow the company.

Could they have waited till after approval, perhaps, but some things might not be available if they waited. Investors might also blame them for not moving ahead fast enough after approval.

I trust management to do what they've determined they need to do now, yes, it costs more in shares, but I trust their judgement that it's better to proceed than wait.

Gary

[Doc logic]

brazen22,

Don’t forget needed regulatory guidance changes, the possible expectation of demand created by expanded off label use beyond initial label approval anticipated by Specials usage and preparations needed for true initial demand which may require a more aggressive ramp up plan than initially anticipated. This would align with plans for additional contracted manufacturing services being talked about.
While waiting for approval we have also seen guidance in the process of changing and increased leukapheresis capacity being prepared for contractually and by centers being set up by NWBO. Sure seems like a whole lot of preparation for something about to go down especially with the new hire announcement. Best wishes.

[Doc logic]

.